No Data
No Data
Sarepta Cut to Neutral at Citi on Risks to Valuation
Sarepta's Expanded Approval Unlikely To Influence Novo Holdings' Acquisition of Catalent, But Provides Investor Protection Amid Uncertainty
Catalent shares rise after Sarepta Therapeutics' Elevidys expanded approval. Despite uncertainties, Catalent's risk/reward profile improves.
Catalent Gains After Sarepta's Elevidys Gets Label Expansion
Pharmaceutical Contract Manufacturing Market Report 2024-2030: Trends, Opportunities and Competitive Analysis Featuring Thermo Fisher Scientific, Catalent, Lonza, Almac Group, and Recipharm
Express News | Shares of Contract Drug Manufacturer Catalent up 3.3% After FDA's Expanded Use Nod for Sarepta's Duchenne Gene Therapy
Japan Contract Development Manufacturing Organization Market Report 2024-2030, Featuring Lonza, Recipharm, LabCorp, Catalent, WuXi AppTec, CordenPharma, Cambrex, Bushu Pharmaceuticals and Nipro